<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453895</url>
  </required_header>
  <id_info>
    <org_study_id>SIRAC-1</org_study_id>
    <nct_id>NCT00453895</nct_id>
  </id_info>
  <brief_title>Sunitinib in Refractory Adrenocortical Carcinoma</brief_title>
  <acronym>SIRAC</acronym>
  <official_title>Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wuerzburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although a first randomized trial in patients with advanced ACC leading to the establishment
      of a first line cytotoxic chemotherapy is ongoing (FIRM-ACT), the failure rate even of this
      FIRM-ACT study is most likely clearly above 50%. Therefore, the majority of participating
      patients urgently need a new treatment option. However, up to date there is no evidence for a
      single regimen that might be promising in these treatment-refractory patients with ACC.

      Sunitinib is an oral multitargeted tyrosine kinase inhibitor with anti-tumor and
      antiangiogenic activities, which is successfully tested in the treatment of patients with
      metastatic renal cell carcinoma, gastrointestinal stromal and neuroendocrine tumors after
      failure of standard cytotoxic chemotherapy.

      The primary objective of this trial is to estimate the response (defined as progression-free
      survival of ≥ 12 weeks) rate associated with Sunitinib treatment in patients advanced ACC
      progressing after cytotoxic chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Clinical Benefit Due to Treatment With Sunitinib</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical benefit was defined as stable disease or better for at least 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Objective Response Rates</measure>
    <time_frame>12 weeks</time_frame>
    <description>Objective Response Rate defined by RECIST 1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Progression-free Survival</measure>
    <time_frame>up to 400 days</time_frame>
    <description>Progression-free survival is defined as time of start of study until documentation of Progress. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Overall Survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Overall Survival was defined as time from start of treatment until death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Toxicity</measure>
    <time_frame>up to 400 days</time_frame>
    <description>Adverse events were rated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (see http://ctep.cancer.gov/reporting/ctc.html).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50mg Sunitinib</description>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of ACC

          -  Locally advanced or metastatic disease not amenable to radical surgery resection

          -  Radiologically monitorable disease

          -  Progressing disease after one to three cytotoxic chemotherapy regimes including a
             platin-based protocol

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 3 months

          -  Age ≥ 18 years

          -  Adequate bone marrow reserve (neutrophils ≥ 1500/mm³ and platelets ≥100.000/mm³) and
             haemoglobin ≥ 9 g/dl

          -  Negative pregnancy test and effective contraception in pre-menopausal female and male
             patients

          -  Patient´s written informed consent

          -  Ability to comply with the protocol procedures

          -  If patients have been participated in another clinical trial evaluating treatment
             options for ACC (e.g. FIRM-ACT), the patient can only be included in the SIRAC trial,
             if:

               -  the patient has discontinued study treatment of the previous trial according to
                  the protocol

               -  or the study chair of the previous trial gives written approval for inclusion of
                  this individual patient in the SIRAC trial.

        Exclusion Criteria:

          -  History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ
             cervical carcinoma, or other treated malignancies with no evidence of disease for at
             least three years.

          -  Severe renal (serum creatinine &gt; 2.5 x ULN) or hepatic insufficiency (ALT / AST &gt; 2.5
             x ULN or ALT/AST &gt;5 x ULN if liver function abnormalities are due to the underlying
             malignancy and/or total serum bilirubin &gt; 2.0 x ULN) and/or serum albumin &lt; 3g/dl

          -  Any of the following within the 8 months prior to study drug administration:
             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
             graft, symptomatic congestive heart failure, cerebrovascular accident or transient
             ischemic attack, pulmonary embolism, or other severe thromboembolic event.

          -  Ongoing cardiac dysrhythmias of NCI CTCAE grade 2, acute atrial fibrillation of any
             grade, or prolongation of the QTc interval to &gt;470 msec for females

          -  Left ventricular ejection fraction (LVEF) &lt;45% as measured by echocardiogram

          -  NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment

          -  Hypertension that cannot be controlled by medications (&gt;160/100 mmHg despite optimal
             medical therapy)

          -  Pregnancy or breast feeding

          -  Previous treatment with Sunitinib or any other VEGF- or PDGF-pathway directed agent.

          -  Current treatment with strong CYP3A4 inhibitors or -inducers

          -  Current treatment with another investigational drug

          -  Current treatment with another anti-cancer drug

          -  Patients with ileus within the last 28 days

          -  Major surgery, radiation therapy, or systemic therapy within 3 weeks of first study
             treatment. At least 7 days should elapse from the time of minor surgical procedure
             including placement of an access device or fine needle aspiration before start of
             study treatment

          -  Serious wounds that have not completely healed, active ulcer(s), or significant bone
             fracture(s).

          -  Prior radiation therapy to &gt;25% of the bone marrow.

          -  Cachectic patients with a body mass index &lt; 18 kg/m2

          -  Any other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Fassnacht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wuerzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Medicine I, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nebennierenkarzinom.ukw.de/startseite.html</url>
    <description>website of the German ACC study group</description>
  </link>
  <results_reference>
    <citation>Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pöllinger A, Laubner K, Strasburger CJ, Hahner S, Müller HH, Allolio B, Fassnacht M. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012 Oct;97(10):3495-503. doi: 10.1210/jc.2012-1419. Epub 2012 Jul 26.</citation>
    <PMID>22837187</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <results_first_submitted>September 6, 2015</results_first_submitted>
  <results_first_submitted_qc>August 25, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2019</results_first_posted>
  <last_update_submitted>August 25, 2018</last_update_submitted>
  <last_update_submitted_qc>August 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Wuerzburg</investigator_affiliation>
    <investigator_full_name>Martin Fassnacht</investigator_full_name>
    <investigator_title>Professor for Medicine and Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Adrenal cancer refractory to cytotoxic therapy</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Multitargeted tyrosine-kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was included in the study on July 17, 2007, the last patient enrolled on September 18, 2009. The last patient stopped the study drug on November 20, 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib</title>
          <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity
Sunitinib :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib</title>
          <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity
Sunitinib :</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Clinical Benefit Due to Treatment With Sunitinib</title>
        <description>Clinical benefit was defined as stable disease or better for at least 12 weeks</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity
Sunitinib :</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Clinical Benefit Due to Treatment With Sunitinib</title>
          <description>Clinical benefit was defined as stable disease or better for at least 12 weeks</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Objective Response Rates</title>
        <description>Objective Response Rate defined by RECIST 1.0</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity
Sunitinib :</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Objective Response Rates</title>
          <description>Objective Response Rate defined by RECIST 1.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Progression-free Survival</title>
        <description>Progression-free survival is defined as time of start of study until documentation of Progress. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>up to 400 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity
Sunitinib :</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Progression-free Survival</title>
          <description>Progression-free survival is defined as time of start of study until documentation of Progress. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="80" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Overall Survival</title>
        <description>Overall Survival was defined as time from start of treatment until death or last follow-up.</description>
        <time_frame>up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity
Sunitinib :</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Overall Survival</title>
          <description>Overall Survival was defined as time from start of treatment until death or last follow-up.</description>
          <units>monhts</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="3.2" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Toxicity</title>
        <description>Adverse events were rated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (see http://ctep.cancer.gov/reporting/ctc.html).</description>
        <time_frame>up to 400 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity
Sunitinib :</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Toxicity</title>
          <description>Adverse events were rated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (see http://ctep.cancer.gov/reporting/ctc.html).</description>
          <units>number of adverse events/patient</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib</title>
          <description>Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
treatment will continue until progressive disease or unacceptable toxicity
Sunitinib :</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocard infarcton</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypogylcimia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>liver failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/drowsiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia, Thrombopenia, Leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash or discolored nails</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A limitation arises from the fact that imaging prior study entry was not standardized. Therefore we cannot provide data regarding the dynamics of tumor growth before initiation of sunitinib.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Dr. Martin Fassnacht</name_or_title>
      <organization>University of Würzburg</organization>
      <phone>+49-931-201-39201</phone>
      <email>fassnacht_m@medizin.uni-wuerzburg.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

